Study Limitations
This investigation has several limitations. First, it was a retrospective single-center study with a small number of subjects, and therefore, the power is limited. Second, selection bias is a potential problem. The renal and hepatic transplant recipients selected for CA might have been healthier and more symptomatic than those who were not selected, and they might also have been more likely to be cared for by arrhythmia specialists. Thus, our patient population may not be representative of the broader population of patients with kidney and liver transplantation. Finally, the rate of absence of AF after CA might be overestimated because of possibility of missing an asymptomatic recurrence of AF. Conclusions
In conclusion, CA for AF is safe and effective in renal and hepatic transplant recipients and may be a suitable treatment for AF in transplant recipients. Larger studies are needed to confirm these results and to investigate the long-term effects of CA in renal and hepatic transplant recipients.